AUTHORS
Ai Guan, MD, Chunyan Sun, MD2, Yan Li3, Yu Wu, MD4, Yini Wang, MD5, Jun Luo, DO6, Weijun Fu, MD, PhD7, Bingzong Li, ????8, Yi Xu Jr, PhD9, Xinyi Xiong, MD10, Chengyang Xu11, Lu Zhang, M.D.12, Zhuang Tian, MD13, Kaini Shen, MD14, Jian Li, MD15
AFFILIATIONS
1 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Institute of Hematology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Department of Hematology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China
4 Department of Hematology and Hematology Research Laboratory, West China Hospital, Sichuan University, Chengdu, China
5 Department of Hematology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
6 Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
7 Department of Hematology, School of Medicine, Shanghai Fourth People's Hospital, Tongji University, Shanghai, China
8 Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, China
9 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
10 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
11 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
12 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
13 Peking Union Medical College Hospital, Beijing, China
14 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
15 Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
ABSTRACT
Background: Mayo stage IIIB light-chain (AL) amyloidosis comprises ~20% of new diagnoses and carries a dismal prognosis. Excluded from the pivotal ANDROMEDA trial, these patients face high early mortality even with standard daratumumab-based regimens, highlighting a critical unmet need. Teclistamab, a BCMA×CD3 bispecific T-cell engager, yields rapid and deep responses in relapsed AL amyloidosis, providing a strong rationale for upfront use. We conducted a phase II multicenter study evaluating first-line teclistamab monotherapy in newly diagnosed Mayo stage IIIB AL amyloidosis.
Methods: This ongoing, single-arm phase II trial (NCT07079423) enrolled adults with newly diagnosed Mayo stage IIIB AL amyloidosis and a difference between involved and uninvolved serum free light chains (dFLC) ≥50 mg/L. Following step-up dosing (0.06 and 0.3 mg/kg), patients received fixed-dose subcutaneous teclistamab (60 mg) on days 8, 15, and 22 of cycle 1, then on day 1 of cycles 2–6 (28-day cycles). The primary endpoint was 1-month stringent FLC response (dFLC <10 mg/L or involved FLC ≤20 mg/L). Hematologic and organ responses were assessed monthly for 3 months, then quarterly. The study complied with the Declaration of Helsinki.
Results: Between June 2025 and June 2026, 24 of 35 planned patients were enrolled (median follow-up: 4.0 months). Median age was 61 years; all had cardiac and 41.7% had renal involvement. Baseline disease was severe: median NT-proBNP was 18,020 ng/L (IQR 10,882–24,728), median dFLC was 344.1 mg/L (75% ≥180 mg/L), and median bone marrow plasma cells was 6%. Hematologic responses were unprecedentedly rapid (median time to first response: 13 days; best response: 36 days). At 1 month, the ≥very good partial response (VGPR) rate was 77.3% (complete response [CR]: 59.1%), stringent FLC response was 72.7%. Among evaluable patients at 3 months (n=16), 68.8% achieved ≥VGPR. For patients surviving beyond 3 months (n=11), best ≥VGPR was 100% and best CR was 90.9%. Cardiac responses were encouraging: best overall cardiac response rate was 54.5%, with 27.3% achieving ≥VGPR. The safety profile was manageable. Grade 3/4 adverse events included lymphopenia (29.2%), pneumonia (12.5%), and neutropenia (4.2%). Eight patients received prophylactic IVIG, among whom only one developed grade 3 pulmonary infection. Cytokine release syndrome (CRS) occurred in 41.6%; all were grade 1–2 except one grade 3 event. Four patients received prophylactic siltuximab, of whom two developed grade 1 CRS. No ICANS was observed. Overall mortality was 33.3% (8/24; progressive heart failure [n=6], infection [n=2]). The 5 early deaths (≤3 months) occurred in patients with extreme baseline cardiac dysfunction (median NT-proBNP: 22,118 ng/L).
Conclusions: Frontline teclistamab monotherapy induces remarkably rapid and profound hematologic responses in newly diagnosed Mayo stage IIIB AL amyloidosis, highlighted by a 13-day median time to response and a 72.7% 1-month stringent FLC response. Although early mortality (29.4% at 3 months) reflects the devastating natural history of this ultra-high-risk population, all patients surviving beyond 3 months achieved deep, sustained responses, with meaningful cardiac recovery in over half of evaluable cases. The safety profile is manageable, with mostly low-grade CRS and no ICANS. Teclistamab represents a highly promising, potent strategy for this vulnerable population.
DISCLOSURES
Ai Guan, MD: No relevant conflicts of interest to declare.